NCI Awards Contract to PGXL for CTC Research | GenomeWeb

NEW YORK (GenomeWeb News) – PGXL Technologies today said that it has been awarded a $300,000 contract from the National Cancer Institute to advance research directed at circulating tumor cells for the early detection of cancer.

The Louisville, Ky.-based firm, a sister company to PGXL Laboratories, uses a technology called DEPArray, developed by Silicon Biosystems. The two firms said in April they were collaborating to make the technology available through PGXL.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.